Nasdaq · Biotech stocks database
CUE (Cue Biopharma Inc.) stock: $18.73, $136.1M market cap, $17.4M cash, $118.7M EV, $285.6M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $17.4M |
|---|---|
| Debt | $0.0M |
| Net cash | $17.4M |
| Enterprise value | $118.7M |
| Basic shares | 7.3M shares |
| Fully diluted shares | 15.3M shares |
| Fully diluted market cap | $285.6M |
| Cash per share | $2.39 |
| Quarterly burn | $29.0M |
| Cash runway | 0.6 quarters |
Cash figures as of 2026-08-12. Database snapshot: 2026-11-07.
Cap table as of 2026-08-12.
Loading CUE daily closes…